Myeloma Multiple Clinical Trials
54 clinical trials for Myeloma Multiple across international registries, including 20 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma — RECRUITING · PHASE2
- A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) — RECRUITING · PHASE3
- The Norwegian Immunotherapy in Multiple Myeloma Study — RECRUITING
- Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial — RECRUITING · PHASE2
- A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma — RECRUITING · PHASE1
- Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma — RECRUITING · NA
- Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS — RECRUITING
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma — RECRUITING · PHASE1
- Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies. — RECRUITING
- MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity — RECRUITING
- Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma — RECRUITING
- Feasibility of a Multi-omics Platform for Hematological Malignancies — RECRUITING · NA
- A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment — RECRUITING · PHASE2
- e-Motion : Promoting Emotion Regulation in Chronic Cancer — RECRUITING · NA
- High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) — RECRUITING
- Limited-duration Teclistamab — RECRUITING · PHASE2
- Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients — RECRUITING · NA
- The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors — RECRUITING · PHASE1
- Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma — RECRUITING
- Fluciclovine PET/CT in Multiple Myeloma Patients — RECRUITING
- Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure — ACTIVE_NOT_RECRUITING · PHASE2
- T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma — COMPLETED · PHASE1
- A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
- Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
- Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma — COMPLETED · PHASE3
- Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma — ACTIVE_NOT_RECRUITING · NA
- Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study — COMPLETED · NA
- Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM — ACTIVE_NOT_RECRUITING · PHASE2
- Bioequivalence Studies of Dasatinib 100 Mg — NOT_YET_RECRUITING · PHASE4
- Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
- Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy — TERMINATED · PHASE2
- Study of the Immune Response After Vaccination in Multiple Myeloma Patients — COMPLETED
- The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood — TERMINATED
- Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM — OTHER
- Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients — TERMINATED · PHASE2
- Corneal Toxicity in Patients Treated by Belantamab Mafodotin — COMPLETED
- Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant — COMPLETED · PHASE2
- Effect of Vitamin C in Autologous Stem Cell Transplantations — COMPLETED · PHASE2
- Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden — COMPLETED
- Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients — COMPLETED · PHASE2
- T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma — COMPLETED · PHASE1
- Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma — TERMINATED · PHASE2
- Rehabilitation Needs of the Malaysian Haematological Cancer Survivors — COMPLETED
- CTFEA Myeloma Study — OTHER
- CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma — OTHER · PHASE1
- CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma — OTHER · PHASE1
- Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma — TERMINATED · PHASE1
- Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma — COMPLETED · PHASE1
- Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive — OTHER · PHASE2
- A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies — OTHER · PHASE1
Refine this search